ES2377012T3 - Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2 - Google Patents

Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2 Download PDF

Info

Publication number
ES2377012T3
ES2377012T3 ES04765681T ES04765681T ES2377012T3 ES 2377012 T3 ES2377012 T3 ES 2377012T3 ES 04765681 T ES04765681 T ES 04765681T ES 04765681 T ES04765681 T ES 04765681T ES 2377012 T3 ES2377012 T3 ES 2377012T3
Authority
ES
Spain
Prior art keywords
galectin
rats
heart failure
level
cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04765681T
Other languages
English (en)
Spanish (es)
Inventor
Yigal M. Pinto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Maastricht
Original Assignee
Universiteit Maastricht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Maastricht filed Critical Universiteit Maastricht
Application granted granted Critical
Publication of ES2377012T3 publication Critical patent/ES2377012T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
ES04765681T 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2 Expired - Lifetime ES2377012T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03078161 2003-10-09
EP03078161A EP1522857A1 (en) 2003-10-09 2003-10-09 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
PCT/EP2004/010879 WO2005040817A1 (en) 2003-10-09 2004-09-27 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2

Publications (1)

Publication Number Publication Date
ES2377012T3 true ES2377012T3 (es) 2012-03-21

Family

ID=34306912

Family Applications (2)

Application Number Title Priority Date Filing Date
ES04765681T Expired - Lifetime ES2377012T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2
ES10186331T Expired - Lifetime ES2530567T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10186331T Expired - Lifetime ES2530567T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2

Country Status (14)

Country Link
US (5) US7888137B2 (OSRAM)
EP (4) EP1522857A1 (OSRAM)
JP (5) JP4840744B2 (OSRAM)
CN (2) CN1879022B (OSRAM)
AT (1) ATE532073T1 (OSRAM)
AU (2) AU2004284496C1 (OSRAM)
CA (2) CA2542033C (OSRAM)
CY (2) CY1112359T1 (OSRAM)
DK (2) DK2317324T3 (OSRAM)
ES (2) ES2377012T3 (OSRAM)
PL (2) PL1682907T3 (OSRAM)
PT (2) PT1682907E (OSRAM)
SI (2) SI2317324T1 (OSRAM)
WO (1) WO2005040817A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
US8153376B2 (en) 2006-09-25 2012-04-10 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
WO2008091948A2 (en) * 2007-01-23 2008-07-31 University Of Virginia Patent Foundation Galectin-3-binding, protein as a biomarker of cardiovascular disease
ATE534912T1 (de) * 2007-09-17 2011-12-15 Bg Medicine Inc Beurteilung des risikos von kongestiver herzinsuffizienz bei patienten, die mit einem peroxisom-proliferator-aktivator-rezeptor-gamma agonisten oder einem thiazolidindion behandelt werden oder möglicherweise damit behandelt werden sollen
AU2009340423B2 (en) * 2008-10-29 2014-07-24 Bg Medicine, Inc. Galectin-3 immunoassay
KR20120104167A (ko) 2009-08-25 2012-09-20 비쥐 메디신, 인코포레이티드 갈렉틴―3 및 심장 재동기화 요법
US20120029003A1 (en) * 2010-07-02 2012-02-02 Bg Medicine, Inc. Galectin-3 and statin therapy
EP2631656B1 (en) * 2010-10-18 2016-07-27 Hideaki Hara Marker for amyotrophic lateral sclerosis, and use thereof
EP2460890A1 (en) * 2010-12-01 2012-06-06 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases
CA2825954A1 (en) * 2011-01-31 2012-08-09 Bg Medicine, Inc. Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
BR112014012823A2 (pt) * 2011-12-08 2015-09-29 Isaac Eliaz redução dos níveis de galectina-3 por meio de plasmaferese
WO2014052803A2 (en) * 2012-09-27 2014-04-03 Siemens Healthcare Diagnostics Inc. Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension
CN104955471A (zh) * 2012-11-15 2015-09-30 塔夫斯大学 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
EP3245515A1 (en) 2015-01-18 2017-11-22 DiaSorin S.p.A. Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker
CN107614168B (zh) * 2015-05-28 2019-10-25 京瓷株式会社 切削工具
CN112553335A (zh) * 2020-12-17 2021-03-26 核工业总医院 肾细胞癌生物标志物及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
EP0988552B1 (en) 1997-06-10 2010-11-24 Lpath, Inc. Methods for early detection of heart disease
EP1018018B1 (en) * 1997-09-05 2010-08-04 Southern Medical Diagnostics Pty Ltd A method of diagnosis
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
CN1149396C (zh) * 1997-10-24 2004-05-12 盐野义制药株式会社 利尿钠肽分解抑制方法及其用该方法分析利尿钠肽的改良方法
DE69939723D1 (de) * 1998-04-02 2008-11-20 Genentech Inc Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
CN1327228C (zh) * 1999-01-29 2007-07-18 罗赫诊断器材股份有限公司 鉴定样品中的n－末端前bnp的方法
DE60031512T2 (de) * 1999-02-19 2007-08-23 University Of Iowa Research Foundation Diagnostika und therapeutika für maculare degeneration
ATE422556T1 (de) * 1999-08-20 2009-02-15 Univ Texas Hdac4- und hdac5-abhängige regulation der genexpression im herzen
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
JP2004532602A (ja) 2000-04-05 2004-10-28 インサイト・ゲノミックス・インコーポレイテッド 泡沫細胞分化において発現される遺伝子
KR100395254B1 (ko) 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
US20030166017A1 (en) * 2000-11-09 2003-09-04 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of cardiovascular disease
WO2002038794A2 (en) * 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
DE60144493D1 (de) * 2000-12-08 2011-06-01 Curagen Corp Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
JP4035562B2 (ja) * 2001-01-31 2008-01-23 国立大学法人富山大学 ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット
CA2441086A1 (en) 2001-03-19 2002-09-26 Wisconsin Alumni Research Foundation Identification of gene expression alterations underlying the aging process in mammals
US20060019235A1 (en) 2001-07-02 2006-01-26 The Board Of Trustees Of The Leland Stanford Junior University Molecular and functional profiling using a cellular microarray
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20030099958A1 (en) * 2001-09-05 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
US20060141493A1 (en) 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
AU2003233147B2 (en) * 2002-05-13 2008-03-06 Arexis Ab Autoimmune conditions and NADPH oxidase defects
WO2004038376A2 (en) 2002-10-24 2004-05-06 Duke University Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
EP1431399A1 (en) * 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
US6889083B2 (en) 2003-04-21 2005-05-03 Medtronic, Inc. Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes
WO2005020784A2 (en) 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
WO2004111654A2 (en) 2003-06-06 2004-12-23 Ciphergen Biosystems, Inc. Serum biomarkers in ischaemic heart disease
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
DE10347436B4 (de) 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
EP1720562A4 (en) 2004-01-15 2009-10-28 Scios Inc METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE
WO2006026074A2 (en) 2004-08-04 2006-03-09 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
WO2006102497A2 (en) 2005-03-22 2006-09-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
US7632634B2 (en) 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
US9592970B2 (en) 2008-07-17 2017-03-14 Toby D. Henderson Robotic gantry with end effector for product lifting
AU2009340423B2 (en) 2008-10-29 2014-07-24 Bg Medicine, Inc. Galectin-3 immunoassay
KR20120104167A (ko) 2009-08-25 2012-09-20 비쥐 메디신, 인코포레이티드 갈렉틴―3 및 심장 재동기화 요법

Also Published As

Publication number Publication date
PT2317324E (pt) 2015-02-17
US20150037353A1 (en) 2015-02-05
DK1682907T3 (da) 2012-08-13
CN1879022B (zh) 2012-10-17
ES2530567T3 (es) 2015-03-03
AU2004284496B2 (en) 2009-08-06
CA2842308A1 (en) 2005-05-06
US20120220532A1 (en) 2012-08-30
EP1522857A1 (en) 2005-04-13
EP1682907A1 (en) 2006-07-26
US8084276B2 (en) 2011-12-27
EP1682907B1 (en) 2011-11-02
CA2542033C (en) 2014-04-29
ATE532073T1 (de) 2011-11-15
AU2009227844B2 (en) 2012-07-19
US20110104722A1 (en) 2011-05-05
PL2317324T3 (pl) 2015-10-30
AU2004284496C1 (en) 2010-03-04
JP2007508527A (ja) 2007-04-05
JP5580774B2 (ja) 2014-08-27
CN1879022A (zh) 2006-12-13
CA2542033A1 (en) 2005-05-06
PL1682907T3 (pl) 2012-03-30
SI1682907T1 (sl) 2012-03-30
EP2317324B1 (en) 2014-11-12
JP2015171365A (ja) 2015-10-01
JP2011177184A (ja) 2011-09-15
JP4840744B2 (ja) 2011-12-21
CY1116147T1 (el) 2017-02-08
AU2009227844A1 (en) 2009-11-26
CN102998458A (zh) 2013-03-27
JP2014115297A (ja) 2014-06-26
CN102998458B (zh) 2015-07-22
WO2005040817A1 (en) 2005-05-06
US7888137B2 (en) 2011-02-15
JP5789009B2 (ja) 2015-10-07
US20130189716A1 (en) 2013-07-25
AU2004284496A1 (en) 2005-05-06
EP2919012A1 (en) 2015-09-16
SI2317324T1 (sl) 2015-11-30
PT1682907E (pt) 2012-02-03
JP2010279378A (ja) 2010-12-16
CY1112359T1 (el) 2015-12-09
US20080193954A1 (en) 2008-08-14
HK1184534A1 (zh) 2014-01-24
HK1101426A1 (en) 2007-10-18
DK2317324T3 (en) 2015-02-16
EP2317324A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
ES2377012T3 (es) Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2
SK2162001A3 (en) Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
JP2025520135A (ja) Ｃｆ４８腎臓損傷バイオマーカー及び腎臓損傷治療薬における用途
US8153376B2 (en) Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
AU2012244071B2 (en) Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
Gao et al. Presenilin2 D439A mutation induces dysfunction of mitochondrial Fusion/Fission dynamics and abnormal regulation of GTPase activity
CN119700741A (zh) 大蒜素在预防和治疗川崎病药物中的应用
Morellato KIAA1217 is a novel protein in the synapse that interacts with PSD-95 and Shank3 andcontrols dendritic spines’ number and morphology
HK1184534B (en) Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
HK1101426B (en) Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
Kaye et al. UltraRapid Communication
Magharious Targeting the Phosphatidylinositide-3 Kinase Pathway and the Mitogen-Activated-Protein Kinase Pathway through Thymosin-β4, Exercise, and Negative Regulators to Promote Retinal Ganglion Cell Survival or Regeneration